サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1784898

アデノ随伴ウイルスベクター製造の世界市場

Adeno Associated Virus Vector Manufacturing

出版日
ページ情報
英文 205 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
アデノ随伴ウイルスベクター製造の世界市場
出版日: 2025年08月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 205 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アデノ随伴ウイルスベクター製造の世界市場は2030年までに34億米ドルに達する見込み

2024年に11億米ドルと推定されるアデノ随伴ウイルスベクター製造の世界市場は、2024～2030年の分析期間でCAGR 20.9%の成長を遂げ、2030年には34億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである臨床規模は、CAGR 22.8%を記録し、分析期間終了時には21億米ドルに達すると予測されます。前臨床事業規模セグメントの成長率は、分析期間中CAGR 18.7%と推定されます。

米国市場は2億8,950万米ドルと推定、中国はCAGR19.6％で成長予測

米国のアデノ随伴ウイルスベクター製造市場は、2024年に2億8,950万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億2,300万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは19.6%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ19.5％と17.9％と予測されています。欧州では、ドイツがCAGR約15.1%で成長すると予測されています。

世界のアデノ随伴ウイルスベクター製造市場- 主要動向と促進要因のまとめ

なぜAAVベクター製造が遺伝子治療の進歩の中心なのか？

AAVベクター製造は画期的な遺伝子治療の進歩の中心にあり、治療遺伝子を標的細胞に送達するための重要なツールとして機能しています。非病原性ベクターであるアデノ随伴ウイルスは、その高い安全性プロファイル、低い免疫原性、分裂している細胞も分裂していない細胞も効率的に導入する能力により、遺伝子導入のゴールドスタンダードとなっています。これらの特性は、遺伝性網膜疾患、血友病、神経疾患など幅広い遺伝性疾患の治療に理想的です。

AAVに基づく遺伝子治療の成功の増加により、スケーラブルで高品質のベクター製造プロセスに対する需要が高まっています。バイオ医薬品企業や研究機関は、臨床試験や商業化製品のニーズの高まりに対応するため、堅牢な製造プラットフォームの開発に多額の投資を行っています。さらに、遺伝子ペイロードの送達におけるAAVベクターの多用途性は、腫瘍学やワクチンなどの新たな分野への応用を拡大しています。

どのような技術革新がAAV製造を形成しているのか？

AAVベクター製造の状況は、スケーラビリティ、効率、品質の向上を目指した技術的進歩によって変化しています。懸濁細胞培養システムなどの大容量生産プラットフォームが従来の接着システムに取って代わりつつあり、コストを削減しながら大規模な製造を可能にしています。最適化されたトランスフェクション技術や高効率の精製方法など、上流および下流工程の革新により、ベクター全体の収量と純度が向上しています。

シングルユース・バイオリアクターと自動化システムの採用により、オペレーションが合理化され、コンタミネーションのリスクが最小限に抑えられ、製造バッチ間の一貫性が確保されています。高度な分析ツールもまた重要な役割を果たしており、AAVベクターの正確な特性評価と品質管理を可能にしています。さらに、人工知能（AI）と機械学習（ML）の統合により、プロセスの最適化、予知保全、トラブルシューティングが強化され、製造ワークフローの効率化が推進されています。

市場需要を牽引する主要エンドユーザーは？

AAVベクター製造の需要は、バイオ製薬会社、学術研究機関、開発・製造受託機関（CDMO）など、幅広い利害関係者に及んでいます。バイオ製薬企業は、AAVベクターを活用して幅広い適応症の遺伝子治療を開発・商品化している主要な牽引役です。これらの企業は、臨床および商業用途のベクターの安定供給を確保するため、強固な製造能力に依存しています。

前臨床試験や初期段階の臨床試験でAAVベクターの革新的な応用を模索している学術・研究機関も重要な貢献者です。CDMOは、中小企業が直面する生産能力の制約に対処し、スケーラブルな製造ソリューションを提供する上で重要な役割を果たしています。希少遺伝性疾患の有病率の上昇とAAVベースの治療法のパイプラインの増加は、医療提供者と規制当局が承認の迅速化と幅広いアクセシビリティを推進することで、顧客基盤をさらに拡大しています。

AAVベクター製造市場の成長を促す要因とは？

アデノ随伴ウイルスベクター製造市場の成長は、広範な疾患を対象としたAAVベースの遺伝子治療のパイプラインの拡大など、いくつかの要因によって牽引されています。製造および精製方法における技術的進歩は、製造プロセスの拡張性と効率を高め、コストを削減し、治療法をより身近なものにしています。遺伝性疾患の有病率の増加と個別化医療の採用拡大もAAVベクターの需要を促進しています。

特に腫瘍学、ワクチン、希少疾患治療などの新興分野における最終用途の多様化は、メーカーに新たな機会をもたらしています。バイオ製薬会社からの投資の増加は、遺伝子治療研究に対する政府および非公開会社からの資金援助と相まって、技術革新と生産能力の拡大を加速させています。さらに、迅速なパスウェイに対する規制当局の支援や先進治療薬の開発を促進するイニシアチブが、AAVベクター製造市場の堅調な成長をさらに後押ししています。

セグメント

事業規模（臨床事業規模、前臨床事業規模、商業事業規模）;方法（インビトロ法、インビボ法）;治療領域（血液疾患治療領域、感染症治療領域、遺伝子疾患治療領域、神経疾患治療領域、眼科疾患治療領域、その他の治療領域）;用途（細胞治療用途、遺伝子治療用途、ワクチン用途）

調査対象企業の例

  • 4D Molecular Therapeutics, Inc.
  • Astellas Gene Therapies
  • BioMarin Pharmaceutical, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • F. Hoffmann-La Roche Ltd.
  • Oxford Biomedica PLC
  • ProBio Inc.
  • REGENXBIO, Inc.
  • Sarepta Therapeutics, Inc.

AIインテグレイションズ

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP28983

Global Adeno Associated Virus Vector Manufacturing Market to Reach US$3.4 Billion by 2030

The global market for Adeno Associated Virus Vector Manufacturing estimated at US$1.1 Billion in the year 2024, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 20.9% over the analysis period 2024-2030. Clinical Scale of Operations, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Preclinical Scale of Operations segment is estimated at 18.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$289.5 Million While China is Forecast to Grow at 19.6% CAGR

The Adeno Associated Virus Vector Manufacturing market in the U.S. is estimated at US$289.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$523.0 Million by the year 2030 trailing a CAGR of 19.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.5% and 17.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.1% CAGR.

Global Adeno Associated Virus Vector Manufacturing Market - Key Trends & Drivers Summarized

Why Is AAV Vector Manufacturing Central to Gene Therapy Advancements?

AAV vector manufacturing is at the heart of revolutionary gene therapy advancements, serving as a critical tool for delivering therapeutic genes to target cells. The adeno associated virus, a non-pathogenic vector, has become the gold standard in gene delivery due to its high safety profile, low immunogenicity, and ability to efficiently transduce both dividing and non-dividing cells. These attributes make it ideal for treating a wide range of genetic disorders, including inherited retinal diseases, hemophilia, and neurological conditions.

The increasing success of AAV-based gene therapies has fueled the demand for scalable, high-quality vector manufacturing processes. Biopharmaceutical companies and research organizations are investing heavily in developing robust manufacturing platforms to meet the growing needs of clinical trials and commercialized products. Furthermore, the versatility of AAV vectors in delivering genetic payloads has expanded their applications to emerging areas such as oncology and vaccines.

What Technological Innovations Are Shaping AAV Manufacturing?

The AAV vector manufacturing landscape is being transformed by technological advancements aimed at enhancing scalability, efficiency, and quality. High-capacity production platforms, such as suspension cell culture systems, are replacing traditional adherent systems, enabling large-scale manufacturing while reducing costs. Innovations in upstream and downstream processes, including optimized transfection techniques and high-efficiency purification methods, are improving overall vector yield and purity.

The adoption of single-use bioreactors and automated systems is streamlining operations, minimizing contamination risks, and ensuring consistency across production batches. Advanced analytical tools are also playing a crucial role, allowing for precise characterization and quality control of AAV vectors. Furthermore, the integration of artificial intelligence (AI) and machine learning (ML) is enhancing process optimization, predictive maintenance, and troubleshooting, driving the efficiency of manufacturing workflows.

Who Are the Key End-Users Driving Market Demand?

The demand for AAV vector manufacturing spans a broad spectrum of stakeholders, including biopharmaceutical companies, academic research institutions, and contract development and manufacturing organizations (CDMOs). Biopharmaceutical firms are the primary drivers, leveraging AAV vectors to develop and commercialize gene therapies for a wide range of indications. These companies rely on robust manufacturing capabilities to ensure the consistent supply of vectors for clinical and commercial applications.

Academic and research institutions are also significant contributors, as they explore innovative applications of AAV vectors in preclinical studies and early-stage clinical trials. CDMOs play a vital role in addressing capacity constraints faced by smaller companies and providing scalable manufacturing solutions. The rising prevalence of rare genetic disorders and the growing pipeline of AAV-based therapies have further expanded the customer base, with healthcare providers and regulatory agencies pushing for accelerated approvals and broader accessibility.

What Factors Are Driving Growth in the AAV Vector Manufacturing Market?

The growth in the adeno associated virus vector manufacturing market is driven by several factors, including the expanding pipeline of AAV-based gene therapies targeting a wide range of diseases. Technological advancements in production and purification methods are enhancing the scalability and efficiency of manufacturing processes, reducing costs and making therapies more accessible. The increasing prevalence of genetic disorders and the growing adoption of personalized medicine are also fueling demand for AAV vectors.

End-use diversification, particularly in emerging areas such as oncology, vaccines, and rare disease treatments, is creating new opportunities for manufacturers. The rising investments from biopharmaceutical companies, coupled with government and private funding for gene therapy research, are accelerating innovation and production capacity expansion. Additionally, regulatory support for expedited pathways and initiatives promoting the development of advanced therapeutics are further driving the robust growth of the AAV vector manufacturing market.

SCOPE OF STUDY:

The report analyzes the Adeno Associated Virus Vector Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Scale of Operations (Clinical Scale of Operations, Preclinical Scale of Operations, Commercial Scale of Operations); Method (In Vitro Method, In Vivo Method); Therapeutic Area (Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area, Neurological Disorders Therapeutic Area, Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas); Application (Cell Therapy Application, Gene Therapy Application, Vaccines Application)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • 4D Molecular Therapeutics, Inc.
  • Astellas Gene Therapies
  • BioMarin Pharmaceutical, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Biogene
  • F. Hoffmann-La Roche Ltd.
  • Oxford Biomedica PLC
  • ProBio Inc.
  • REGENXBIO, Inc.
  • Sarepta Therapeutics, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Adeno Associated Virus Vector Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Demand for Gene Therapy and Advanced Biopharmaceuticals
    • Expansion of Clinical Trials and FDA Approvals for Gene-Based Treatments
    • Increasing Investments in Biopharma R&D and Viral Vector Production
    • Advancements in Scalable and Cost-Effective Manufacturing Techniques
    • Growing Use of AAV Vectors in Rare Disease Treatment and Personalized Medicine
    • Increasing Adoption of CRISPR and Other Gene Editing Technologies
    • Expansion of CDMO Capabilities in Viral Vector Production
    • Rising Interest in AAV for Neurological and Ophthalmic Disorder Therapies
    • Enhanced Purification and Quality Control Technologies Driving Market Growth
    • Government Funding and Incentives Supporting Gene Therapy Advancements
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Adeno Associated Virus Vector Manufacturing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Clinical Scale of Operations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Clinical Scale of Operations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Preclinical Scale of Operations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Preclinical Scale of Operations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Commercial Scale of Operations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Commercial Scale of Operations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Ophthalmic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Ophthalmic Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other Therapeutic Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other Therapeutic Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hematological Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Hematological Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Infectious Diseases Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Infectious Diseases Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Genetic Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Genetic Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Neurological Disorders Therapeutic Area by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Neurological Disorders Therapeutic Area by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Cell Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Cell Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Gene Therapy Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Gene Therapy Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for In Vitro Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for In Vitro Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for In Vivo Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for In Vivo Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • JAPAN
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • CHINA
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • EUROPE
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • FRANCE
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • GERMANY
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • UNITED KINGDOM
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Adeno Associated Virus Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Scale of Operations - Percentage Breakdown of Value Sales for Clinical Scale of Operations, Preclinical Scale of Operations and Commercial Scale of Operations for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Therapeutic Area - Percentage Breakdown of Value Sales for Ophthalmic Disorders Therapeutic Area, Other Therapeutic Areas, Hematological Diseases Therapeutic Area, Infectious Diseases Therapeutic Area, Genetic Disorders Therapeutic Area and Neurological Disorders Therapeutic Area for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Application - Cell Therapy Application, Gene Therapy Application and Vaccines Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Application - Percentage Breakdown of Value Sales for Cell Therapy Application, Gene Therapy Application and Vaccines Application for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Adeno Associated Virus Vector Manufacturing by Method - In Vitro Method and In Vivo Method - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Adeno Associated Virus Vector Manufacturing by Method - Percentage Breakdown of Value Sales for In Vitro Method and In Vivo Method for the Years 2025 & 2030

IV. COMPETITION